학사 : 조선대학교 약학대학 약학과, 순천향대학교 의료과학대학 의료생명공학과
석·박사 : 전남대학교 약학대학 약학과(생물약제학)

1. Research Topic (30 Aug. 2024 ~ 20 Apr. 2025) Editor for the Frontiers in Antibiotics (Title: Precision medicine approach based on pharmacokinetics/pharmacodynamics of antibiotics). https://www.frontiersin.org/research-topics/67015/precision-medicine-approach-based-on-pharmacokineticspharmacodynamics-of-antibiotics).
2. Public Relations Secretary (홍보간사, 01 Jan. 2024 ~ 31 Dec. 2025), Korean Society of Toxicology
3. Information Secretary (정보간사, 01 Jan. 2024 ~ 31 Dec. 2024), The Korean Society of Pharmaceutical Sciences and Technology
4. Information Secretary (정보간사, 01 Jan. 2023 ~ 31 Dec. 2023), The Korean Society of Pharmaceutical Sciences and Technology
5. Special Issue (02 Dec. 2022 ~ 25 Mar. 2024) Guest Editor for the Pharmaceuticals (Special Issue: Pharmacometrics Research for the Realization and Advancement of Precision Medicine). https://www.mdpi.com/journal/pharmaceuticals/special_issues/2999F0JOJ6).
6. Special Issue (29 Aug. 2022 ~ 31 Mar. 2023) Guest Editor for the Pharmaceutics (Special Issue: Approaches to Individualized Drug Therapy Based on Population Pharmacometrics). https://www.mdpi.com/journal/pharmaceutics/special_issues/3BWA61U074
7. Assistant Professor (01 Sep. 2022 ~ Present), Department of Pharmacy, Sunchon National University (Suncheon-si, Korea)

약물계량모델링, 분자모델링 및 머신러닝, 인체위해성 평가

1. J.-H. Jang, S.-H. Jeong*, Population pharmacokinetic modeling study and discovery of covariates for the antidepressant sertraline, a serotonin selective reuptake inhibitor, Comput. Biol. Med., 183, 109319 (2024). *Corresponding author
2. J.-H. Jang, H.-S. Kang, S.-H. Jeong*, Population Pharmacokinetics of Loxoprofen and its alcoholic metabolites in healthy Korean men, DARU J. Pharm. Sci., In-press (2024). *Corresponding author
3. J.-H. Jang, S.-H. Jeong*, Human risk assessment through development and application of a physiologically based toxicokinetic model for 4-tert-octylphenol, Environ. Pollut., 360, 124613 (2024). *Corresponding author
4. J.-H. Jang, S.-H. Jeong*, Structure-based analysis of cefaclor pharmacokinetic diversity according to human peptide transporter-1 genetic polymorphism, Int. J. Mol. Sci., 25(13), 6880 (2024). *Corresponding author
5. H.-B. Sim, J.-S. Son, S.-K. Gupta, S.-H. Jeong, Y.-J. Choi, J.-Y. Han, S.-C. Ramos, H.-G. Kim, D.-H. Park, H.-J. Yoo, Y.-J. Yoo, D.-J. Chang, S.-K. Mun, Y.-H Seo, J.-J. Kim, Development of Hsp90 inhibitor to regulate cytokine storms in excessive delayed- and acute inflammation, Int. Immunopharmacol., 137, 112470 (2024).
6. S.-M. Lee‡, J.-H. Jang‡, S.-H. Jeong*, Exploring gender differences in pharmacokinetics of central nervous system related medicines based on a systematic review approach, Naunyn-Schmiedeberg’s Arch. Pharmacol., 397, 8311-8347 (2024). ‡Co-first authors, *Corresponding author
7. J.-H. Jang, J.-H. Jeong, S.-H. Jeong*, Quantitative summary on the human pharmacokinetic properties of cannabidiol to accelerate scientific clinical application of cannabis, Naunyn-Schmiedeberg’s Arch. Pharmacol., 397, 8285-8309 (2024). *Corresponding author
8. J.-H. Jang‡, Y.-J. Cho‡, S.-H. Jeong*, Pharmacokinetic analysis of levodropropizine and its potential therapeutic advantages considering eosinophil levels and clinical indications, Pharmaceuticals, 17(2), 234 (2024). ‡Co-first authors, *Corresponding author
9. S.-H. Jeong‡, J.-H. Jang‡, Y.-B. Lee, Is gender an important factor in the precision medicine approach to levocetirizine?, Pharmaceutics, 16(1), 146 (2024). ‡Co-first authors
10. S.-H. Jeong‡, J.-H. Jang‡, H.-Y. Cho, Y.-B. Lee, Sex differences in 4-tert-octylphenol toxicokinetics: Exploration of sex as an effective covariate through an in vivo modeling approach, Toxicology, 502, 153733 (2024). ‡Co-first authors
11. S.-H. Jeong‡, J.-H. Jang‡, Y.-B. Lee, Population pharmacokinetic modeling of levodropropizine: Extended application to comparative analysis between commercial formulations and exploration of pharmacokinetic effects of diet, Naunyn-Schmiedeberg’s Arch. Pharmacol., 397, 4403-4418 (2024). ‡Co-first authors
12. S.-H. Jeong‡, J.-H. Jang‡, Y.-B. Lee, Modeling population pharmacokinetics of morniflumate in healthy Korean men: Extending pharmacometrics analysis to niflumic acid, its major active metabolite, Naunyn-Schmiedeberg’s Arch. Pharmacol., 397, 843-856 (2024). ‡Co-first authors
13. S.-H. Jeong‡, J.-H. Jang‡, Y.-B. Lee, Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic–Pharmacodynamic Modeling, Biomedicines, 11(11), 3021 (2023). ‡Co-first authors
14. J.-H. Jang‡, S.-H. Jeong‡, Y.-B. Lee, A population pharmacokinetic model for individualized regimens of finasteride according to CYP3A5 genotype and liver function, J. Pharm. Investig., 53, 857-868 (2023). ‡Co-first authors
15. S.-H. Jeong‡, J.-H. Jang‡, Y.-B. Lee, P-glycoprotein mechanical functional analysis using in silico molecular modeling: pharmacokinetic variability according to ABCB1 c.2677G>T/A genetic polymorphisms, Int. J. Biol. Macromol., 249, 126777 (2023). ‡Co-first authors
16. S.-H. Jeong‡, J.-H. Jang‡, Y.-B. Lee, Inter-individual exposure variability interpretation through reflection of biological age algorithm in physiologically based toxicokinetic model: Application to human risk assessment of di-isobutyl-phthalate, Environ. Pollut., 336, 122388 (2023). ‡Co-first authors
17. J.-H. Jang‡, S.-H. Jeong‡, Y.-B. Lee, Quantitative assessment of the relevance of organic-anion-transporting-polypeptide 1B1 and 2B1 polymorphisms in fexofenadine pharmacokinetic variants via pharmacometrics, J. Pharm. Anal., 13(6), 660-672 (2023). ‡Co-first authors
18. J.-H. Jang‡, S.-H. Jeong‡, Y.-B. Lee, Establishment of a fexofenadine population pharmacokinetic (PK)–pharmacodynamic (PD) model and exploration of dosing regimens through simulation, J. Pharm. Investig., 53, 427-441 (2023). ‡Co-first authors
19. J.-H. Jang‡, S.-H. Jeong‡, Y.-B. Lee, Population Pharmacokinetic Modeling of Zaltoprofen in Healthy Adults: Exploring the Dosage Regimen, Pharmaceuticals, 16(2), 161 (2023). ‡Co-first authors
20. J.-H. Jang‡, S.-H. Jeong‡, Y.-B. Lee, Dosage exploration of meloxicam according to CYP2C9 genetic polymorphisms based on a population pharmacokinetic-pharmacodynamic model, Pharmacotherapy, 43, 145-157 (2023). ‡Co-first authors
21. S.-H. Jeong‡, J.-H. Jang‡, Y.-B. Lee, Drug delivery to the brain via the nasal route of administration: Exploration of key targets and major consideration factors, J. Pharm. Investig., 53, 119-152 (2023). ‡Co-first authors
22. S.-H. Jeong‡, J.-H. Jang‡, Y.-B. Lee, Torsemide Pharmacometrics in Healthy Adult Populations Including CYP2C9 Genetic Polymorphisms and Various Patient Groups through Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling, Pharmaceutics, 14(12), 2720 (2022). ‡Co-first authors
23. S.-H. Jeong, J.-H. Jang, Y.-B. Lee, Physiologically based pharmacokinetic (PBPK) modeling of lornoxicam: Exploration of doses for CYP2C9 genotypes and patients with cirrhosis, J. Pharm. Sci., 111(11), 3174-3184 (2022).
24. S.-H. Jeong, J.-H. Jang, Y.-B. Lee, Development of physiologically-based toxicokinetic-toxicodynamic (PBTK-TD) model for 4-nonylphenol (4-NP) reflecting physiological changes according to age in males: Application as a new risk assessment tool with a focus on toxicodynamics, Environ. Pollut., 312, 120041 (2022).
25. S.-H. Jeong‡, J.-H. Jang‡, H.-Y. Cho, Y.-B. Lee, Human risk assessment of 4-n-nonylphenol (4-n-NP) using physiologically-based pharmacokinetic (PBPK) modeling: Analysis of gender exposure differences and application to exposure analysis related to large exposure variability in population, Arch. Toxicol., 96(10), 2687-2715 (2022). ‡Co-first authors
26. S.-H. Jeong‡, J.-H. Jang‡, H.-Y. Cho*, Y.-B. Lee, Population pharmacokinetic (Pop-PK) analysis of torsemide in healthy Korean males considering CYP2C9 and OATP1B1 genetic polymorphisms, Pharmaceutics, 14(4), 771 (2022). ‡Co-first authors
27. S.-H. Jeong‡, J.-H. Jang‡, Y.-B. Lee, Population pharmacokinetic analysis of lornoxicam in healthy Korean males considering creatinine clearance and CYP2C9 genetic polymorphism, J. Pharm. Investig., 52 (1), 109-127 (2022). ‡Co-first authors
28. S.-H. Jeong, J.-H. Jang, H.-Y. Cho, Y.-B. Lee, Toxicokinetic studies of di-isobutyl phthalate focusing on the exploration of gender differences in rats, Chemosphere, 286, 131706 (2022)
29. S.-H. Jeong‡, J.-H. Jang‡, H.-Y. Cho, Y.-B. Lee, Toxicokinetics of di-isodecyl phthalate and its major metabolites in rats through the application of a developed and validated UHPLC-ESI-MS/MS method, Arch. Toxicol. 95, 3515-3537 (2021). ‡Co-first authors
30. S.-H. Jeong‡, J.-H. Jang‡, Y.-B. Lee, Pharmacokinetic Comparison between Methotrexate-Loaded Nanoparticles and Nanoemulsions as Hard- and Soft-Type Nanoformulations: A Population Pharmacokinetic Modeling Approach, Pharmaceutics, 13(7), 1050 (2021). ‡Co-first authors
31. S.-H. Jeong‡, J.-H. Jang‡, Y.-B. Lee, Oral delivery of topotecan in polymeric nanoparticles: lymphatic distribution and pharmacokinetics, J. Control. Release, 335, 86-102 (2021). ‡Co-first authors
32. S.-H. Jeong, J.-H. Jang, H.-Y. Cho, Y.-B. Lee, Human risk assessment of di-isobutyl phthalate through the application of a developed physiologically based pharmacokinetic model of di-isobutyl phthalate and its major metabolite mono-isobutyl phthalate, Arch. Toxicol., 95(7), 2385-2402 (2021)
33. S.-H. Jeong‡, J.-H. Jang‡, H.-Y. Cho*, Y.-B. Lee, Population pharmacokinetic analysis of cefaclor in healthy Korean subjects, Pharmaceutics, 13(5), 754 (2021). ‡Co-first authors
34. S.-H. Jeong, J.-H. Jang, D.-H. Jung, G.-Y. Lee, Y.-B. Lee, Pharmacokinetic Changes According to Single or Multiple Oral Administrations of Socheongryong-Tang to Rats: Presented as a Typical Example of Changes in the Pharmacokinetics Following Multiple Exposures to Herbal Medicines, Pharmaceutics, 13(4), 478 (2021)
35. S.-H. Jeong, J.-H. Jang, G.-Y. Lee, S.-J Yang, H.-Y. Cho, Y.-B. Lee, In vivo and in vitro studies of Banhahoobak-tang tablets using UPLC-ESI-MS/MS with polarity switching, J. Pharm. Biomed. Anal., 196, 113931 (2021)
36. S.-H. Jeong‡, J.-H. Jang‡, H.-Y. Cho, Y.-B. Lee, Pharmacokinetic comparison with different assays for simultaneous determination of cis-, trans-cefprozil diastereomers in human plasma, J. Pharm. Anal., 11(3), 351-363 (2021). ‡Co-first authors
37. S.-H. Jeong, J.-H. Jang, G.-Y. Lee, S.-J Yang, H.-Y. Cho, Y.-B. Lee, Simultaneous determination of fourteen components of Gumiganghwal-tang tablet in human plasma by UPLC-ESI-MS/MS and its application to pharmacokinetic study, J. Pharm. Anal., 11(4), 444-457 (2021)
38. S.-H. Jeong, J.-H. Jang, H.-Y. Cho, Y.-B. Lee, Simultaneous determination of asarinin, β-eudesmol, and wogonin in rats using ultraperformance liquid chromatography–tandem mass spectrometry and its application to pharmacokinetic studies following administration of standards and Gumiganghwal-tang, Biomed. Chromatogr., 35(4), e5021 (2021)
39. S.-H. Jeong, J.-H. Jang, H.-Y. Cho, Y.-B. Lee, Simultaneous determination of three iridoid glycosides of Rehmannia glutinosa in rat biological samples using a validated hydrophilic interaction-UHPLC-MS/MS method in pharmacokinetic and in vitro studies, J. Sep. Sci., 43(22), 4148-4161 (2020)
40. J.-H. Jang, S.-H. Jeong, Y.-B. Lee, Enhanced lymphatic delivery of methotrexate using W/O/W nanoemulsion: In vitro characterization and pharmacokinetic study, Pharmaceutics, 12(10), 978 (2020)
41. S.-H. Jeong, J.-H. Jang, H.-Y. Cho, Y.-B. Lee, Toxicokinetics of diisobutyl phthalate and its major metabolite, monoisobutyl phthalate, in rats: UPLC-ESI-MS/MS method development for the simultaneous determination of diisobutyl phthalate and its major metabolite, monoisobutyl phthalate, in rat plasma, urine, feces, and 11 various tissues collected from a toxicokinetic study. Food. Chem. Toxicol., 145, 111747 (2020)
42. S.-H. Jeong‡, J.-H. Jang‡, Y.-B. Lee, Pharmacokinetic comparison of three different administration routes for topotecan hydrochloride in rats. Pharmaceuticals, 13(9), 231 (2020). ‡Co-first authors
43. S.-H. Jeong, J.-H. Jang, H.-Y. Cho, Y.-B. Lee, Simultaneous measurement of epinastine and its metabolite, 9,13b-dehydroepinastine, in human plasma by a newly developed ultra-performance liquid chromatography–tandem mass spectrometry and its application to pharmacokinetic studies, Biomed. Chromatogr., 34(9), e4848 (2020)
44. S.-H. Jeong, J.-H. Jang, H.-Y. Cho*, Y.-B. Lee, Risk assessment for humans using physiologically based pharmacokinetic model of diethyl phthalate and its major metabolite, monoethyl phthalate, Arch. Toxicol., 94(7), 2377-2400 (2020)
45. S.-H. Jeong‡, J.-H. Jang‡, H.-Y. Cho, Y.-B. Lee, Population pharmacokinetic analysis of tiropramide in healthy Korean subjects. Pharmaceutics, 12(4), 374 (2020). ‡Co-first authors
46. S.-H. Jeong, J.-H. Jang, H.-Y. Cho, Y.-B. Lee, Pharmacokinetic comparison of epinastine using developed human plasma assays, Molecules, 25(1), 209 (2020)
47. S.-H. Jeong, J.-H. Jang, H.-Y. Cho, I.-J. Oh*, Y.-B. Lee, A sensitive UPLC–ESI–MS/MS method for the quantification of cinnamic acid in vivo and in vitro: application to pharmacokinetic and protein binding study in human plasma. J. Pharm. Investig., 50(2), 159-172 (2020)
48. S.-H. Jeong‡, J.-H. Jang‡, H.-Y. Cho*, Y.-B. Lee, Gender differences in pharmacokinetics and tissue distribution of 4-n-nonylphenol in rats, Arch. Toxicol., 93(11), 3121-3139 (2019). ‡Co-first authors
49. J.-H. Jang‡, S.-H. Jeong‡, H.-Y. Cho, Y.-B. Lee, Population pharmacokinetics of cis-, trans-, and total cefprozil in healthy male Koreans, Pharmaceutics, 11(10), 531 (2019). ‡Co-first authors
50. S.-H. Jeong, J.-H. Jang, G.-Y. Lee, S.-J Yang, H.-Y. Cho, Y.-B. Lee, Simultaneous determination of fourteen main active components in Gumiganghwal-tang tablet by using a newly developed UPLC-ESI-MS/MS method, J. Chromatogr. B, 1126-1127, 121743 (2019)
51. S.-H. Jeong, J.-H. Jang, Y.-B. Lee, A novel and sensitive UPLC–MS/MS method to determine mequitazine in rat plasma and urine: Validation and its application to pharmacokinetic studies, Biomed. Chromatogr., 33(10), e4627 (2019)
52. S.-H. Jeong‡, J.-H. Jang‡, H.-Y. Cho, Y.-B. Lee, Simultaneous determination of diethyl phthalate and its major metabolite, monoethyl phthalate, in rat plasma, urine, and various tissues collected from a toxicokinetic study by ultrahigh performance liquid chromatography-tandem mass spectrometry, J. Pharm. Biomed. Anal., 173, 108-119 (2019). ‡Co-first authors
53. J.-H. Jang, S.-H. Jeong, Y.-B. Lee, Preparation and in vitro/in vivo characterization of polymeric nanoparticles containing methotrexate to improve lymphatic delivery, Int. J. Mol. Sci., 20(13), 3312 (2019)
54. J.-H. Jang‡, S.-H. Jeong‡, H.-Y. Cho, Y.-B. Lee, Comparison of UPLC-MS/MS and HPLC-UV methods for the determination of zaltoprofen in human plasma, J. Pharm. Investig., 49(6), 613-624 (2019). ‡Co-first authors
55. S.-H. Jeong, J.-H. Jang, S.-H. Ham, S.-J Yang, H.-Y. Cho, Y.-B. Lee, Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study, J. Chromatogr. B, 1095, 214-225 (2018)
56. S.-H. Jeong, J.-H. Jang, H.-Y. Cho, Y.-B. Lee, Soft- and hard-lipid nanoparticles: a novel approach to lymphatic drug delivery, Arch. Pharm. Res., 41(8), 797-814 (2018)
57. Phuong Tran, J.-H. Jang, S.-H. Jeong, Y.-B. Lee, Oral and Lymphatic Delivery of Paclitaxel via Lipid Nanocapsules, Yakhak Hoeji, 65(5), 375-385 (2021)

● UPLC-MS/MS (질량분석기)

● 동물실험장비 (소동물흡입용마취시설, 샘플링 보정기)

● 분석 라이센스 softwares

● Microfludizer (나노입자제조기)

● Particle analyzer (입자 특성 분석기)

● 동결건조기

Pharmacometrics, Pharmacokinetics/Pharmacodynamics, Toxicokinetics/Toxicodynamics, Risk assessment, Population pharmacometrics modeling, Physiologically-based pharmacometrics modeling, Molecular modeling, Lymphatic delivery
Nanoparticle formulation and evaluation, Bioanalytical method development and validation, AI/Machine learning